Use of systemic glucocorticoids in therapy of infectious diseases

Česká verzia

Authors: Lucie Hromádková ^1,2
Authors place of work: Oddělení klinické farmacie, Nemocnice Na Homolce, Praha ¹; Oddělení klinické farmacie Lékárny Masarykovy nemocnice Ústí nad Labem ²
Published in the journal: Vnitř Lék 2016; 62(2): 134-138
Category: Reviews

Summary

Glucocorticoids have been known and used in clinical practice for many years now, still their position in the treatment of infectious diseases is continuously developing. Still there are only few review papers focusing on their use in this area. This article summarizes the present knowledge of possible use of glucocorticoids in therapy of infectious diseases. Despite the known contraindication of these agents in the case of acute infections, there have been areas identified where the results of clinical assessments indicate possible benefit. Given the complexity of the problems and sometimes controversial conclusions, each administration of glucocorticoids to a patient with an infectious disease should be preceded by a careful consideration and assessment of an individual benefit and possible risks following from the treatment.

Key words:
glucocorticoids – infectious diseases

Zdroje

1. Stuck AE, Minder CE, Fre FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989; 11(6): 954–963.

2. Cutolo M, Seriolo B, Pizzorni C et al. Use of glucocorticoids and risk of infections. Autoimmun Rev 2008; 8(2): 153–155.

3. Cronin L, Cook DJ, Carlet J et al. Corticosteroid treatment for sepsis: A critical appraisal and meta-analysis of the literature. Crit Care Med 1995; 23(8): 1430–1439.

4. Lefering R, Neugebauer E. Steroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med 1995; 23(7): 1294–1303.

5. Annane D, Bellissant E, Bollaert PE et al. Corticosteroids for treating severe sepsis and septic shock. Cochrane Database System Rev 2004; (1): CD002243.

6. Mason PE, Al-Khafaji A, Milbrandt EB et al. CORTICUS: The end of unconditional love for steroid use? Crit Care 2009; 13(4): 309.

7. Dellinger RP, Levy MM, Rhodes A et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41(2): 580–637.

8. Canfalonieri M, Urbino R, Potena A et al. Hydrocortisone infusione for severe community acquired pneumonia. A preliminary randomized study. Am J Respir Crit Care Med 2005; 171(3): 242–248.

9. Garcia-Vidal C, Calbo E, Pascual V et al. Effects of systemic steroids in patients with severe community-acquired pneumonia. Eur Respir J 2007; 30(5): 951–956.

10. Marik P, Kraus P, Sribante J et al. Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia: a randomized controlled study. Chest 1993; 104(2): 389–392.

11. Sabry NA, El-Din Omar E. Corticosteroids and ICU-course of community acquired pneumonia in Egyptian settings. Pharmacol Pharm 2011; 2(2): 73–81.

12. Meijvis S, Hardeman H, Remmelts HHF et al. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. Lancet 2011; 377(9782): 2023–2030.

13. Snijders D, Daniels JMA, de Graaff CS et al. Efficacy of corticosteroids in community-acquired pneumonia. Am J Respir Crit Care Med 2010; 181(9): 975–982.

14. McHardy VU, Schonell ME. Ampicillin dosage and use of prednisolone in treatment of pneumonia: co-operative controlled trial. Brit Med J 1972; 4(5840): 569–573.

15. Gorman SK, Slavik RS, Marin J. Corticosteroid treatment of severe community-acquired pneumonia. Ann Pharmacother 2007; 41(7): 1233–1237.

16. Torres A, Sibila O, Ferrer M et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA 2015; 313(7): 677–686.

17. de Gans J, van de Beek D. European dexamethasone in adulthood bacterial meningitis study investigators. Dexamethasone in adults with bacterial meningitis. N Engl J Med 2002; 347(20): 1549–1556.

18. Scarborough M, Gordon SB, Whitty CJM et al. Corticosteroids for bacterial meningitis in adults in sub-Saharan Africa. N Engl J Med 2007; 357(24): 2441–2450.

19. Nguyen TH, Tran TH, Twaites G et al. Dexamethasone in Vietnamese adolescents and adults with bacterial meningitis. N Engl J Med 2007; 357(24): 2431–2440.

20. Brouwer MC, McIntyre P, Prasad K et al. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev 2013; 6: CD004405.

21. Smego RA, Ahmed N. A systematic review of the adjunctive use of systemic corticosteroids for pulmonary tuberculosis. Int J Tuber Lung Dis 2002; 7(3): 208–213.

22. Tuberculosis Research Centre. Study of chemotherapy regimens of 5 and 7 months’ duration and the role of corticosteroids in the treatment of sputum-positive patients with pulmonary tuberculosis in South India. Tubercle 1983; 64(2): 73–91.

23. Mayanja-Kizza H, Jones-Lopez E, Okwera A et al. Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a phase 2 clinical trial in Uganda. J Infect Dis 2005; 15; 191(6): 856–865.

24. Prasad K, Volmink J, Menon GR. Steroids for treating tuberculous meningitis. Cochrane Database System Rev 2000; (3): CD002244.

25. Thwaites GE, Nguyen DB, Nguyen HD et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 2004; 351(17): 1741–1751.

26. Prasad K, Singh MB. Corticosteroids for managing tuberculous meningitis. Cochrane Database Syst Rev 2008; (1): CD002244.

27. Thwaites G, Fisher M, Hemingway C et al. British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children. J Infect 2009; 59(3): 167–187.

28. Marx GE, Chan ED. Tuberculous meningitis: diagnosis and treatment overview. Tuberc Res Treat 2011; 2011: 798764. Dostupné z DOI: http://dx.doi.org/10.1155/2011/798764.

29. American Thoracic Society; CDC; Infectious Diseases Society of America. Treatment of tuberculosis. MMWR Recomm Rep 2003; 52 (RR-11): 1–77. Erratum in MMWR Recomm Rep 2005; 53(51): 1203.

30. Mayosi BM, Ntsekhe M, Volmink JA et al. Interventions for treating tuberculous pericarditis. Cochrane Database System Rev 2002; (4): CD000526.

31. Hakim JG, Ternouth I, Mushangi E et al. Double-blind randomised placebo-controlled trial of adjuvant prednisolone in the treatment of effusive tuberculous pericarditis in HIV seropositive patients. Heart 2000; 84(2): 183–188.

32. Strang JIG, Kakaza HHS, Gibson DG et al. Controlled clinical trial of complete open surgical drainage and of prednisolone in treatment of tuberculous pericardial effusion in Transkei. Lancet 1988; 2(8614): 759–764.

33. Strang JI, Nunn AJ, Johnson DA et al. Management of tuberculous constrictive pericarditis and tuberculous pericardial effusion in Transkei: results at 10 years follow-up. QJM 2004; 97(8): 525–535.

34. Mayosi BM, Ntsekhe M, Bosch J et al. Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis. N Engl J Med 2014; 371(12): 1121–1130.

35. Odio CM, Ramirez T, Arias G et al. Double blind, randomized, placebo-controlled study of dexamethasone therapy for hematogenous septic arthritis in children. Pediatr Infect Dis J 2003; 22(10): 883–888.

36. Harel L, Prais D, Bar-On E et al. Dexamethasone therapy for septic arthritis in children: results of a randomized double-blind placebo-controlled study. J Pediatr Orthop 2011; 31(2): 211–215.

37. Aberdein J, Singer M. Clinical review: A systematic review of corticosteroid use in infections. Critical Care 2006; 10(1): 203.

38. Wood MJ, Johnson RW et al. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med 1994; 330(13): 896–900.

39. Whitley RJ, Weiss H, Gnann JW et al. Acyclovir with and without prednisone for the treatment of herpes zoster: a randomized, placebo-controlled trial. Ann Intern Med 1996; 125(5): 376–383.

40. Esmann V, Kroon S, Peterslund NA et al. Prednisolone does not prevent post-herpetic neuralgia. Lancet 198; 2(8551): 126–129.

41. Clemmensen OJ, Andersen KE. ACTH versus prednisone and placebo in herpes zoster treatment. Clin Exp Dermatol 1984; 9(6): 557–563.

42. Eaglstein WH, Katz R, Brown JA. The effects of early corticosteroid therapy on the skin eruption and pain of herpes zoster. JAMA 1970; 211(10): 1681–1683.

43. Candy B, Hotopf M. Steroids for symptom control in infectious mononucleosis. Cochrane Database Syst Rev 2006; 19(3): CD004402.

44. Luzuriaga K, Sullivan JL. Infectious mononucleosis. N Engl J Med 2010; 362(21): 1993–2000.

45. Briel M, Bucher HC, Boscacci R et al. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV-infection. Cochrane Database Syst Rev 2006; 19(3): CD006150.

46. Pareja JG, Garland R, Koziel H. Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. Chest 1998; 113(5): 1215–1224.

47. Delclaux C, Zahar JR, Amraoui G et al. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in non-human immunodeficiency virus-infected patients: retrospective study of 31 patients. Clin Infect Dis 1999; 29(3): 670.

48. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. [2.4.2015]. Dostupné z WWW: http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf.